Cyclin-dependent kinase 9 (CDK9) promotes transcriptional elongation through RNAPII pause release. We now report that CDK9 is also essential for maintaining gene silencing at heterochromatic loci. Through a live cell drug screen with genetic confirmation, we discovered that CDK9 inhibition reactivates epigenetically silenced genes in cancer, leading to restored tumor suppressor gene expression, cell differentiation, and activation of endogenous retrovirus genes. CDK9 inhibition dephosphorylates the SWI/SNF protein BRG1, which contributes to gene reactivation. By optimization through gene expression, we developed a highly selective CDK9 inhibitor (MC180295, IC50 = 5 nM) that has broad anti-cancer activity in vitro and is effective in in vivo cancer models. Additionally, CDK9 inhibition sensitizes to the immune checkpoint inhibitor a-PD-1 in vivo, making it an excellent target for epigenetic therapy of cancer.
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In Brief
Inhibition of a kinase typically associated with transcription elongation complexes leads to reactivation of tumor suppressor genes and increases sensitivity to immunotherapy in cancer models.
INTRODUCTION
Epigenetic reprogramming in cancer leads to heritable changes in gene expression, such as silencing of tumor suppressor genes (TSG) (Jones et al., 2016) . These altered epigenetic marks come about as a result of aging and acquisition of genetic and epigenetic changes in readers/writers/editors of the epigenome (Issa, 2014; Jones et al., 2016) . DNA methylation in the promoter of TSGs results in gene silencing through recruitment of methylbinding domain (MBD) proteins such as MeCP2 (Jones et al., 2016; Taby and Issa, 2010) . In turn, MBDs recruit repressor complexes resulting in heterochromatin formation (Nan et al., 1998) . Reversing epigenetic modifications by drugging the epigenome led to the field of epigenetic therapy. However, clinically, epigenetic treatment options remain limited.
Cyclin-dependent kinases (CDKs) come in two partially overlapping classes-regulators of the cell cycle (e.g., CDK1, CDK2, CDK4, CDK6, and CDK7) and regulators of transcription (e.g., CDK7-CDK9 and CDK10-CDK13). CDK9, the catalytic subunit of P-TEFb, is a transcriptional activator recruited to promote RNAPII promoter-proximal pause release by phosphorylating negative elongation factors (DSIF and NELF) (Adelman and Lis, 2012; Garriga and Grañ a, 2004) . CDK9-mediated phosphorylation of the C-terminal domain (CTD) of RNAPII on serine-2 allows recruitment of RNA processing factors, which work on the nascent RNA as it emerges from RNAPII. P-TEFb promotes transcriptional elongation of several signal-responsive genes that regulate proliferation, development, stress, and/or damage responses (Adelman and Lis, 2012; Garriga and Grañ a, 2004) such as MYC (Rahl et al., 2010) , nuclear factor kB (NF-kB) (Barboric et al., 2001) , and MCL1 (MacCallum et al., 2005) .
We have been using the YB5 cell-based system derived from the human colon cancer cell line, SW48, as a platform for epigenetic drug screens (Raynal et al., 2012) . YB5 contains a single insertion of the cytomegalovirus (CMV) promoter driving the GFP gene. GFP is silenced in YB5 by epigenetic mechanisms including DNA hypermethylation leading to closed chromatin formation, and its expression can be reactivated by treatment with DNA methylation inhibitors and/or HDAC inhibitors. In a screen for GFP reactivation in YB5, we identified a novel drug class that reactivates silenced genes by targeting CDK9 without affecting DNA methylation. We show that CDK9 is required for 
RESULTS

Identification of CDK9 as a Novel Epigenetic Target
Phenotypic screens provide an unbiased approach for identifying targets and drugs. We screened YB5 against the NDL-3040 natural compound library (Figure S1A) . This assay had a z-factor of 0.6, indicating adequacy for high-throughput screening. At a stringent criterion for GFP induction ([mean of all compounds] + 3 SD), 33 compounds (1.1%) were positive. A further selection of hits with R25% relative activity compared to the positive control yielded 18 compounds, 15 of which were successfully validated by 24-hr dose curves, fluorescence microscopy, and qPCR. Five of these hits had similar structures including an aminothiazole core (Figure S1A ). Structure and data on HH0, a representative aminothiazole compound, are shown in Figures 1A, S1B, and S1C. We started chemical optimization by screening a library of 93 aminothiazole analogs at multiple doses (ranging from 2.5 mM to 50 mM) and identified HH1 as the most potent ( Figure S1A ). HH1 was active at 5 mM in YB5 (Figure 2A) and was also validated in HCT116-GFP, a colon cancer cell line where GFP is inserted downstream of the hypermethylated promoter SFRP1 (Cui et al., 2014) , and in MCF7-GFP, a breast cancer line derived by introducing GFP under the control of a methylated CMV promoter ( Figure S1D ). Thus, HH1 can reactivate silenced GFP in three distinct live cell assays.
Chemically, aminothiazole compounds do not resemble known epigenetic drugs. To determine their relevant target(s), we first studied DNA methylation and found no demethylation at either CMV or LINE-1 (measured by bisulfite pyrosequencing, data not shown) or globally (measured by reduced representation bisulfite sequencing [RRBS] ), indicating that they are not DNMT inhibitors (Figure S1E ). We next used biochemical assays to analyze a panel of HDACs (class I, IIb, and IV) and found no inhibitory activity (Figure S1F) . We also screened HH1 against a panel of 30 histone methylases and demethylases and found no significant inhibition of enzymatic activity (Figure S1G ; Table S3 ). We then measured global histone acetylation and methylation after 48 hr treatment with HH1 and found no significant changes, except for a modest increase in H3K79 methylation, a mark of transcriptional elongation ( Figure S1H ). Thus, HH1 had no substantial activity against the main known regulators of epigenetic silencing.
We next used connectivity mapping (Lamb et al., 2006) , which identifies drugs with similar transcriptional profiles. Using RNA sequencing (RNA-seq) after HH1 treatment for 24 hr, the closest drugs to HH1 were CDK inhibitors. To validate these unexpected targets, we tested 7 different CDK inhibitors, and they all induced GFP in YB5 with a range of 5%-15% after 24 hr (Figure 1B) . The fact that these drugs with diverse chemical structures (Figure 1B) are all active suggests that CDKs are indeed the relevant drug targets. We also tested the expression of SYNE1 and MGMT, two known genes hypermethylated in YB5 and found that HH1 and other CDK inhibitors (flavopiridol and iCDK9) (Lu et al., 2015) led to gene reactivation after 24 hr treatment (Figure 1C) .
The tested drugs target many CDKs but the ones most effective at gene reactivation had the lowest IC50s against CDK9 (Figure S1I) . To genetically validate CDK9 as a regulator of gene silencing, we used an inducible dominant negative CDK9 (dnCDK9). We found striking re-expression of GFP and of endogenously silenced genes upon induction of dnCDK9 (Figures 1D and S1J) . This effect could also be seen in HCT116-GFP cells (Figure S1K) . By contrast, dnCDK1 or dnCDK2 showed no effects (Figure S1L) . Conversely, activation of GFP and endogenously silenced genes by HH1 and other CDK inhibitors was completely prevented by overexpression of P-TEFb (CDK9 + cyclin T1) (Figures 1E and S1M) . Collectively, these data strongly suggest that CDK9 is the target of the newly identified aminothiazole compounds and is therefore required to maintain transcriptional repression at epigenetically silenced loci.
Development of Novel CDK9 Inhibitors
We next tested newly synthesized HH1 analogs for gene expression-based structure activity relationship (SAR) discovery. A time course qPCR showed that a one-dose 4-day treatment with 25 mM HH1 induced the highest levels of GFP and hypermethylated genes in YB5 (Figure S3A ). We tested 77 novel aminothiazole analogs using this approach and identified MC180295 as the most potent (active at 50 nM and leading to $60% GFP + cells at 500 nM) (Figure 2A) , together with three analogs with similar activities (Figures 2A and S2A) . We tested the selectivity of MC180295 against a panel of 250 kinases at 1 mM and found it to be highly selective against CDKs within the human kinome, although glycogen synthase kinase 3 (GSK-3a and GSK-3b) was also inhibited ( Figure 2B ; Table S4 ). Two specific GSK-3 inhibitors (CHR99021 and LiCl) showed no GFP reactivation in YB5, suggesting that GSK-3 is not relevant to gene activation (Figure S2C) . We then generated a dose-response curve for MC180295 against 10 different CDKs. The drug was most active against CDK9 (IC50 = 5 nM) and was at least 22-fold more selective for CDK9 over other CDKs (Figures 2C and S2B) . To confirm on-target (C) Reactivation of GFP, SYNE1, and MGMT 24 hr after treatment with CDK9 inhibitors as detected by qPCR. (D) Reactivation of GFP, SYNE1, and MGMT 72 hr after dominant-negative CDK9 (dnCDK9) overexpression (TET-off) detected by qPCR. HH1 (25 mM, 24 hr) was used as a positive control. The western blot (right) shows that dnCDK9 is overexpressed when cells are grown in the absence of tetracycline together with decreased phosphorylation of RNA Pol ll at Ser2 (pSer2). (E) Overexpression of P-TEFb (CDK9 and cyclin T1) for 72 hr abolished the effect of CDK9 inhibitors (24 hr) on the activation of GFP, SYNE1, and MGMT as detected by qPCR. Depsipeptide was used as a negative control (uninhibited by CDK9 overexpression). The western blot (right) shows the overexpression of CDK9 and cyclin T1 72 hr after viral transduction. Single transduction of CDK9 or cyclin T1 was used as a size control. See also Figure S1 and Table S3 . selective CDK9 inhibition, we measured phosphorylation levels of Ser2 (pSer2) on the heptad repeats of the CTD of RNAPII, which is phosphorylated by P-TEFb, at different doses after 2 hr MC180295 treatment. Ser2 was dephosphorylated at nanomolar doses, while substrates of CDK4/6 (Calbó et al., 2002; Harbour et al., 1999) were only affected at substantially higher doses, and CDK1/2 substrates were not affected at all (Figures 2D and  S2D) . Similar results were seen after 8 hr of MC180295 treatment ( Figure S2E ). Thus, optimization of HH1 based on gene expression alone yielded a highly specific CDK9 inhibitor.
To understand MC180295 specificity, we built a model of the CDK9-MC180295 complex. From its planar aminothiazole core with alternating hydrogen bond donors and acceptors, we surmised that MC180295 would be an ATP-competitive inhibitor with a pattern of interactions matching other kinase inhibitors (Wang et al., 2014) . Based on this, we elected to model the structure of MC180295 bound to CDK9 by analogy to other ligands in complex with CDKs. We first compiled a set of all 389 structures of CDKs with bound ligands available in the Protein Data Bank (PDB). As described in the STAR Methods, we structurally aligned low-energy conformations of MC180295 to each of these ligands and then replaced the kinase structure with that of CDK9. We refined these models and found that a single dominant cluster emerged among the top-scoring complexes (i.e., an identical binding mode in 14 of the top 30 models). We took this as the predicted pose for the MC180295-CDK9 complex and examined this model further.
In our model, the aminothiazole core makes canonical hydrogen bonding interactions to the CDK9 hinge region. Although it was not included among our templates, the interactions that emerge mimic closely those made by dasatinib, a broad-spectrum inhibitor that is also built on an aminothiazole core ( Figure 2E ). Like dasatinib, MC180295 is modeled in a ''DFG-in'' conformation (making it a type I inhibitor), and its binding mode strongly resembles that of the CDK4/6 inhibitor palbociclib (Lu and Schulze-Gahmen, 2006) . Whereas palbociclib hydrogen bonds directly to the backbone of the DFG motif, however, MC180295 uses a nitro group to engage the Lys-Glu salt bridge that is invariant in essentially all kinases; a similar interaction to this has also been observed in the structure of CDK9 bound to the multi-CDK inhibitor flavopiridol (alvocidib) (Baumli et al., 2008) (Figure 2E ). The strong similarity in this part of the binding site among CDKs, coupled with the similarity of these interactions to those of other multi-CDK inhibitors, implied that the basis for CDK9-selectivity did not derive from this part of the compound.
On the opposite site of the MC180295 model, a norbornyl group fits on top of the C terminus of the hinge region and occupies a shallow hydrophobic cleft. This region of the binding site is also occupied by many other inhibitors of CDKs; however, each of these uses individual (flat) ring structures instead of the bulkier norbornane. Careful comparison among all CDK crystal structures available in the PDB revealed a subtle difference: the C-terminal part of the CDK9 hinge region can adopt a slightly lower conformation that distinguishes it from the other CDKs where this loop has a higher conformation that sterically prevents the norbornyl group from being accommodated ( Figure 2E) . Thus, this model explains the observed SAR for analogs of MC180295 and this compound's preference for CDK9 over other CDKs.
CDK9 Inhibition Leads Epigenetic Derepression
Genome-wide To characterize CDK9 targets dynamically, we performed a time course qPCR on GFP and SYNE1. They could both be induced as early as 8 hr, and their expression levels peaked 4 days after a single exposure ( Figure S3A ). To confirm that the gene induction is associated with on-target CDK9 inhibition, we measured the expression of MYC, a known P-TEFb target and found it to be suppressed at all these time points (Figure S3B ). The timing of gene expression activation is likely related to the fact that chromatin remodeling at silenced loci requires time and cell division. However, it could also be related to selection of drug resistant survivor cells at 4 days. To exclude this, we measured drug sensitivity of survivor cells by culturing them drug-free for 2 weeks and re-exposing them to drugs. Rather than resistance, we observed that ''survivors'' of CDK9 inhibition were even more sensitive to re-treatment, indicating delayed sensitization, an effect typical of epigenetic drugs (Figure S3C) .
We next performed time course RNA-seq using HH1 (Figure S3D ). Short-term CDK9 inhibition (2 hr, 4 hr) led mainly to gene downregulation (e.g., 1,242 genes down versus 404 genes up at 2 hr). Gene Ontology analysis showed that genes downregulated after 2 hr were enriched for regulation of transcription (Figure S3E) . These started to recover by 4 hr and showed delayed upregulation as previously shown for P-TEFb targets (Garriga and Grañ a, 2014; Lu et al., 2015) (Figure S3F ). In contrast to (D) Quantification of western blots 2 hr after MC180295 treatment against pSer2 (CDK9 target), phosphor-Rb at T870/811, phosphor-Rb at T826, p130 (CDK4/6 targets), phosphor-CDK substrate motif (K/H)pSP, and phosphor-PRC1 (CDK1/2 targets). At 500 nM (top), there is specific inhibition of CDK9 only while at 5 mM, CDK9, CDK4, and CDK6 are inhibited. Data on other doses are in Figure S2D . (E) In our model (green), the aminothiazole core of MC180295 engaged the CDK9 hinge region (left) with interactions that mimic that of dasatinib (shown here bound to cSrc, PDB: 3G5D, pink). MC180295 engaged the conserved Lys48-Glu66 hydrogen bond (green) (middle); the multi-CDK inhibitor flavopiridol also made a similar interaction (PDB: 3BLR, pink). The norbornyl group from MC180295 requires that the C terminus of the hinge region adopts a slightly lower conformation; this conformation is shared amongst the many crystal structures of CDK9 (right) (yellow: structures of CDK9 bound to ATP and to another type I inhibitor [PDB: 3BLQ and 4BCJ] and our model of MC180295), but this loop conformation is rarely observed in structures of other CDK kinases (blue: representative structures of CDK1, CDK2, CDK5, CDK6, and CDK7, each bound to ATP or a type I inhibitor [PDB: 5LQF, 1HCK, 1UNH, 2EUF, and 1UA2]). See also Figure S2 and Table S4 . .1) after excluding genes downregulated at 2 hr/4 hr. dnCDK9 (72 hr), DAC (100 nM daily for 48 hr), and combinatorial treatment (100 nM DAC daily for 48 hr followed by a single10 mM HH1 exposure for 4 days) were also included. (C) Percentage of genes upregulated by HH1, dnCDK9, DAC, and combinatorial treatment that have low (0%-10%), moderate (10%-50%), or high (50%-100%) promoter DNA methylation measured by RRBS.
this early response, we observed massive gene upregulation (2,981 up versus 278 down) 4 days after first drug exposure. Even after excluding the P-TEFb targets identified earlier (downregulated at 2 hr/4 hr), we still observed upregulation of 2,597 genes. This large effect (12.3% of the transcriptome) was consistent with the GFP data. Over the entire transcriptome, the effect of HH1 on gene upregulation was predominant at 4 days (mean induction of 1.4-fold), and the effect was most profound for silenced genes (mean induction of >4-fold) (Figures 3A and S3G) . To better characterize this, we focused on the 1,806 genes that showed low expression at baseline (reads per kilobase million [RPKM] <0.31) and that were induced by HH1 ( Figure 3B ). Most of these silenced/upregulated genes were highly hypermethylated in their promoters ( Figure 3C ). While expression peaked at 4 days on average, they generally showed progressive induction, starting to be detectable at 4-8 hr after treatment (Figure 3D) . Gene Ontology analysis showed that they were enriched for cell adhesion, a signature also seen for upregulated genes after treatment with the DNMT inhibitor decitabine (DAC) ( Figure S3H ). To compare gene reactivation by CDK9 versus DNMT inhibition, we selected 10 hypermethylated genes reactivated by HH1 and validated their expression dynamics using MC180295, as compared to DAC. Eight out of 10 hypermethylated genes could be reactivated by MC180295 as early as 8 hr after drug treatment, and their expression levels peaked after 4-day CDK9 inhibition. This reversal of gene silencing happened faster than could be achieved with DAC; for most of these, reactivation by DAC took at least 24 hr and also peaked at 4 days ( Figure S3I ). The data above indicate that HH1 has a bimodal effect (one gene subset downregulated early and another upregulated late). To verify that this is due to CDK9 inhibition, we examined RNA-seq after dnCDK9. Principal component analysis of the entire transcriptome showed that the baseline conditions (cells treated with DMSO at different time points and TET-on dnCDK9) clustered together, and there was a time-dependent progressive gene induction after HH1 treatment ( Figure 3E ). Strikingly, dnCDK9 overexpression clustered closest to 4-day HH1 treatment, and there was a strong correlation between HH1 and dnCDK9 effects by RNA-seq ( Figure 3F ). Genes upregulated after either HH1 4-day treatment or dnCDK9 overexpression had very low baseline expression, consistent with the hypothesis that CDK9 is essential to maintain epigenetic silencing ( Figure 3G) .
Interestingly, the transcriptional profiles of DNMT inhibition (by DAC) clustered closely to 4-day HH1 ( Figure 3E ), and upstream analysis of genes induced by HH1 showed a strong enrichment for genes induced by DAC ( Figure 3H ). Because HH1 did not induce demethylation, we tested for synergy between HH1 and DAC. The two drugs were highly synergistic for GFP and SYNE1 reactivation ( Figure S3A ). The synergistic effects were validated using either siDNMT1 or siCDK9 ( Figure S3J ). We next performed RNA-seq using DAC in combination with HH1. After excluding the early response genes (downregulated at 2 hr/4 hr), we found that, compared to DAC alone (1,238 up versus 7 down) or HH1 alone (1,806 up versus 13 down), silenced genes (RPKM <0.31) were significantly upregulated by the combination (3,948 up versus 3 down) ( Figure 3A) . Thus, long-term CDK9 inhibition shows similar transcriptional profiles to DNMT inhibition and exhibits synergy with DNMT inhibition.
BRG1 Is a Direct Phosphorylation-Substrate of CDK9
In a search for the mechanism of CDK9-mediated repression, we examined ingenuity pathway analysis (IPA) of the RNA-seq data on genes upregulated by HH1. SMARCA4, a member of the SWI/ SNF family of genes, was one of the top activated regulators (Figure 3H) . SMARCA4, also known as BRG1, is an ATP-dependent helicase that is a central component of the SWI/SNF family and can use ATP hydrolysis to regulate chromatin structure (St Pierre and Kadoch, 2017) . To test if CDK9 inhibition affects chromatin structure, we used Assay for Transposase-Accessible Chromatin sequencing (ATAC-seq) and examined cells before and after HH1 treatment (at 4 days). ATAC-seq data (done in triplicate) showed that both before and after HH1, there was a strong correlation between chromatin relaxation and gene expression ( Figure S4A ). When normalized using highly expressed genes that do not change after drug treatment, we found that HH1 results in striking global and diffuse relaxation of chromatin, suggesting that CDK9 is required for maintenance of heterochromatin compaction ( Figure 4A ). Examples of ATAC-seq peaks appearing after HH1 treatment are shown in Figure 4B . Consistent with this, we found higher occupancy of H3K4me2 at the promoter regions of hypermethylated CDK9 targeted genes after HH1 treatment ( Figures S4B and S4C) .
Based on the above, we hypothesized that CDK9 regulates BRG1 by direct phosphorylation. Publicly available proteomic data showed possible binding of CDK9 to BRG1 (Rouillard et al., 2016) . We used co-immunoprecipitation (coIP) to confirm this. We first performed an immunoprecipitation (IP) using a FLAG-tagged CDK9 construct in HEK293T and successfully pulled down BRG1 ( Figure 4C ). Next, we overexpressed FLAGtagged BRG1 in SW48, the parental cell line of YB5, and also (D) Dynamics of gene expression for silenced genes (baseline RPKM <0.31) that were significantly upregulated (FC >2, FDR <0.1) 4 days after HH1. The yellow dotted lines represent 2-fold change. (E) 3D principal component analysis of RNA-seq data upon DMSO (in blue) or HH1 10 mM treatment (in green) (n = 3). Also shown are dnCDK9 (72 hr) (in gold [TETon] and orange [TET-off] ), 48 hr daily DAC treatment at 100 nM (in pink), and sequential combinatorial treatment (100 nM DAC daily for 48 hr followed by HH1 at 10 mM [in red]) (n = 3). DMSO and TET-on (dnCDK9-off) clustered together and are circled in red (baseline). DAC, TET-off (dnCDK9-on) and 4-day HH1 also clustered together and are circled in blue (long-term). Different time points are shown in different shapes and labeled in the legend. (F) Gene expression changes after HH1 (y axis) recapitulate the effect of dominant negative CDK9 (x axis). Concordant changes are in orange, discordant changes in blue, changes smaller than 2-fold are in grey. The numbers in each quadrant show genes with >2-fold expression change and % of total genes. (G) Density plots show the distribution of differentially expressed genes (log 2 fold change on y axis and log 2 RPKM on x axis) after HH1 treatment at 10 mM or dnCDK9 overexpression (72 hr). The red lines represent no change. (H) Ingenuity pathway analysis of upstream regulators of genes activated by HH1 based on genes in (D) . See also Figure S3 . successfully pulled down CDK9 ( Figure 4D ). We then overexpressed GFP-tagged CDK9 and successfully pulled down BRG1 ( Figure 4D ). To confirm these interactions, we performed reciprocal endogenous coIPs in both HEK293T and YB5 ( Figures  4E and 4F) . IP of BRG1 successfully pulled down CDK9 along with other SWI/SNF complex members ( Figure S4D ). IP of CDK9 pulled down BRG1 along with its P-TEFb complex partner, cyclin T1 ( Figure S4E) .
We next performed an in vitro kinase assay using purified CDK9 and BRG1 proteins and found that CDK9 directly phosphorylates BRG1 in vitro ( Figure 4G ). To identify potential phosphorylation sites in BRG1 regulated by CDK9 inhibition, we performed liquid chromatography-tandem mass spectrometry (LC-MS/MS) using purified recombinant active CDK9 and BRG1 proteins in the presence or absence of drug treatment. In an experiment run in quadruplicate, we identified a series of five serine residues at the C-terminal domain of BRG1 as phosphorylation targets of CDK9 ( Figure S4F ). These residues are highly conserved across different species (Figure S4F) and are just downstream of the bromodomain of BRG1. Publicly available data showed that these serine residues could also be found phosphorylated in vivo in cancer (Hornbeck et al., 2015) .
BRG1 Is Essential for Gene Reactivation by CDK9 Inhibition
To confirm that BRG1 phosphorylation is relevant to gene activation by CDK9 inhibitors, we overexpressed BRG1 in YB5. BRG1 overexpression significantly enhanced the effects of CDK9 inhibitors on GFP reactivation ( Figure 4H ), a finding that was confirmed using different BRG1 expression vectors ( Figures  S4G-S4J ). Using sensitive confocal microscopy, we found that BRG1 overexpression alone could activate GFP, albeit at low levels ( Figure 4H ). We generated a BRG1 expression vector where all 5 serine sites identified as phosphorylated by CDK9 were mutated to alanine to generate a de-phosphomimetic construct mirroring CDK9 inhibition. This de-phosphomimetic BRG1 alone could also trigger GFP induction ( Figure 4H ) and showed an even greater synergy when combined with MC180295 ( Figure 4H ). We then deleted these five serines and found that the truncated BRG1 behaved similarly to the de-phosphomimetic construct ( Figures 4H, S4I , and S4J). To test whether BRG1 is required for gene activation, we inhibited BRG1 expression by siRNA prior to treatment with CDK9 inhibitors and found significantly reduced GFP induction ( Figure S4K ). We also used the BRG1 inhibitor PFI-3 (Vangamudi et al., 2015) and found that it inhibited GFP activation by CDK9 inhibitors in a dose-dependent manner ( Figure S4L ).
If the SWI/SNF complex is involved in gene reactivation, one would expect to see effects on chromatin. Indeed, as described earlier, CDK9 inhibition resulted in broad opening of chromatin as measured by ATAC-seq. Moreover, when we merged RNA-seq data with H3K9me2 chromatin immunoprecipitation sequencing (ChIP-seq) data in YB5, we found that the HH1-upregulated genes were highly enriched for H3K9me2 at baseline (Figure S4M ). We validated this enrichment at the CMV-GFP locus and at the promoters of MGMT and SYNE1 by ChIP-qPCR (Figure S4N ). Also, we showed earlier that CDK9 inhibition resulted in site-specific increases in H3K4me2, consistent with chromatin relaxation. Collectively, the data suggest a model whereby CDK9-mediated phosphorylation of BRG1 prevents it from being recruited to heterochromatin loci, while CDK9 inhibition allows BRG1 to remodel chromatin and alter gene expression.
CDK9 Inhibition Has Anti-tumoral Effects In Vitro and
In Vivo Anti-tumoral effects of CDK9 inhibition have been attributed to MCL1 and/or MYC suppression, but these studies were based on drugs that inhibit multiple CDKs. For example, the ''prototypical'' CDK9 inhibitor flavopiridol also inhibits CDK1 and CDK4 (IC50 20 nM for CDK9, 30 nM for CDK1, 100 nM for CDK4, etc.) (Asghar et al., 2015) . We therefore tested whether more specific CDK9 inhibitors have anti-tumoral effects. We tested proliferation 4 days after one-time HH1 or MC180295 exposure. Compared to a normal lung fibroblast (IMR90), both HH1 and MC180295 were more effective in reducing proliferation of cancer cells ( Figure 5A ). Cell-cycle analysis showed no cell-cycle arrest after HH1 or MC180295 ( Figure S5A ), but an increase in the sub-G1 subpopulation ( Figure S5B ). We next tested colony formation in soft agar and found that a single dose pre-exposure of HH1 and MC180295 for 4 days can blunt colony formation by . We also tested effects on the differentiation marker CD11b using the HL60 cell line and found significant induction ( Figures 5D  and S5C ). Last, we tested in vivo effects of MC180295 and the structurally related CDK9 inhibitor, SNS-032. We subcutaneously injected SW48 into NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NSG) mice and treated them every other day (qod) for 10 weeks at 20 mg/kg. We found that tumors grew slower after drug treatment and MC180295 improved mouse survival ( Figure 5E ) without causing overt toxicity as measured by body weight (Figure S5D) . Similar data were obtained in an experiment where luciferase labeled SW48 were injected intraperitoneally (i.p.) into NSG mice followed by MC180295 treatment (Figures S5F-S5H). Analysis of tumor tissues showed that GFP and a (C) BRG1 immunoprecipitates with transfected FLAG-tagged CDK9 in HEK293T. (D) Top: CDK9 immunoprecipitates with transfected FLAG-tagged BRG1. Bottom: BRG1 immunoprecipitates with transfected GFP-tagged CDK9 in SW48. (E) Endogenous coIPs in HEK293T. (F) Endogenous coIPs in SW48. IgG was used as a negative control for (E) and (F) . The IgG heavy chain (Hc) was also shown in (F) . ( See also Figure S4 . hypermethylated CDK9 target gene (GLD) were reactivated in vivo after 2 weeks of drug exposure ( Figure S5E ). Last, we transplanted an ovarian cancer mouse cell line, ID8, into syngeneic immunocompetent mice and tested the anti-tumor efficacy of SNS-032. 10 mg/kg SNS-032 given qod reduced tumor burden and extended survival ( Figure 5F ). In this cell line, we also saw reactivation of ovarian cancer-specific hypermethylated TSGs upon CDK9 inhibition ( Figure S5I ).
CDK9 Inhibition Activates Endogenous Retroviruses and an Interferon Response
DNMT inhibitors can trigger the IFNg pathway within tumor cells, in part by activation of endogenous retroviruses (ERVs), leading to epigenetic immunosensitization (Chiappinelli et al., 2015; Roulois et al., 2015) . RNA-seq after HH1 identified DNMTi and interferon (IFN)g signatures ( Figure 3H ). We therefore analyzed ATAC-seq and RNA-seq data after HH1 treatment. There was a significant increase in the number of ATAC-seq reads coming from repetitive elements after drug treatment (Figures 6A and S6A) . RNA-seq data showed that multiple repetitive elements were induced ( Figure 6A ), including ERVs. We validated four of the ERVs by qPCR in SW48 ( Figure 6B ) and HCT116 ( Figure S6B ). HLA-A, HLA-B, and HLA-C were all significantly upregulated upon CDK9 inhibition. PD-L1, an IFNg inducer, was downregulated early after CDK9 inhibition but rebounded to baseline levels by 4 days ( Figure S6C ). Next, as previously shown for DNMTi (Chiappinelli et al., 2015) , we identified 326 immune-related genes that could be activated by HH1 ( Figure S6D ). This CDK9 immune signature (CIM) was queried in The Cancer Genome Atlas (TCGA) database (Cancer Genome Atlas Network, 2015) and identified a subset of melanoma patients carrying high expression of CIM and significantly better outcomes ( Figure 6C ). A similar pattern was found in colon cancer (Cancer Genome Atlas Network, 2012) ( Figure S6E ). We then queried RNA-seq data from 19 melanoma patients treated with anti-CTLA4 (Snyder et al., 2014) and found that the subset of cases with long-term benefit tended to have a higher expression level of CIM signature genes ( Figure S6F ). These data supported the hypothesis that CDK9 inhibition could sensitize to immune checkpoint inhibitors. We directly tested this in the ID8 mouse model and found that CDK9 inhibition could sensitize to anti-PD1 in vivo ( Figure 5F ). CDK9 inhibition increased the numbers of CD45 + immune cells and the percentages of CD3 + T cells and activated dendritic cells in the tumor environment, while combining CDK9 inhibition with checkpoint blockage further boosted the immune responses in vivo ( Figures 6D and S6G) . Finally, we injected human peripheral blood mononuclear cells directly into NSG mice followed by either 10 mg/kg or 20 mg/kg MC180295 treatment for 14 days. We found that MC180295 did not kill human T lymphocytes and did not affect the ratio of CD4 and CD8 T cells in vivo ( Figures 6E and S6H) . Thus, in addition to having single-agent anti-tumoral activity, CDK9 inhibition is a promising strategy for epigenetic immunosensitization.
DISCUSSION
Epigenetic mediators of gene silencing are validated cancer targets (Jones et al., 2016). Here, we report on a novel epigenetic silencing target-CDK9-and a new inhibitor that shows nanomolar potency and has 20-fold selectivity for CDK9 compared to other CDKs. Reactivation of silenced genes requires cell division to help reset chromatin (Cui et al., 2014) ; thus, optimization using gene expression also selects against drugs that inhibit the cell cycle. This may explain why the drug discovered shows high selectivity for CDK9 compared to cell-cycle regulating CDKs. Our model of the CDK9-MC180295 complex suggests that this inhibitor achieves selectivity through the norbornyl group, by taking advantage of a subtle structural variation in the active site. This general principle has emerged as a paradigm to explain the selectivity of other selective type I inhibitors as well (Wang et al., 2014) .
To our knowledge, this is the first time that CDK9 is linked to gene silencing in mammals. The data pointing to CDK9's role in epigenetic silencing are based on the effects of pharmacologic (exquisitely specific drugs) and genetic manipulation (dominant negative) of CDK9, as well as overexpression of CDK9 that blocks the effects of the drugs on gene silencing. In terms of timing and targets, this gene induction pattern is broadly similar to what is seen with DNMTi, and the synergy with DNMTi suggests potential pathways for clinical development. CDK9 inhibition reactivates genes by remodeling chromatin but without affecting DNA methylation, as previously seen with HDAC inhibition (Raynal et al., 2012) .
CDK9-mediated phosphorylation of SWI/SNF complex components, including BRG1, has previously been reported in HIV-1 infected T cells, and phosphorylation of the SWI/SNF component Baf53 can lead to its release from DNA (Van Duyne et al., 2011) . We hypothesize that CDK9-mediated phosphorylation of BRG1 can lead to its release from chromatin. The specific phosphorylation sites we identified are near the bromodomain of BRG1, and mutations or deletion of these sites enhances the effects of BRG1 on gene activation, suggesting that phosphorylation of this domain keeps the BAF complex away from heterochromatin. We propose that CDK9 inhibition triggers a cascade of events that start with allowing BRG1 to remodel chromatin, followed by nucleosomal sliding, access to activating histone modifiers, and ultimately, access to transcription factors that result in gene activation. Given that BRG1 overexpression alone only modestly activates gene expression, it is likely that CDK9 inhibition also has other effects on the gene silencing machinery. It is interesting to consider why CDK9 evolved to simultaneously maintain high-level gene expression (at super-enhancer driven loci) and gene silencing (at heterochromatin loci). Rapidly cycling cells have the potential for transcription ''errors'' due to the need to remodel chromatin for DNA replication, and it is likely that proteins such as CDK9 evolved to ensure fidelity of expression (both high and low) at newly replicated loci. In this context, it will be interesting to determine whether other CDKs are also involved in gene silencing.
CDK targeting has been an active area of research in oncology. CDK4/6 inhibitors were developed to treat cyclin D-dependent cancers and were approved by the U. S. Food and Drug Administration for treating ER-positive and HER2-negative breast cancer (Sherr et al., 2016) . A recent report on immune effects of CDK4/6 inhibition (Goel et al., 2017 ) may explain their activity as combination therapeutics, and it is broadly similar to what we observed here with CDK9 inhibition. In fact, the CDK4/CDK6 inhibitor used in these studies also inhibits CDK9 (Sherr et al., 2016) , suggesting the possibility that some of the effects seen were also due to CDK9 inhibition. CDK7/ CDK9 targeting has previously been proposed as a strategy to suppress the expression of super-enhancer driven oncogenes (e.g., MYC) (Wang et al., 2015) . Moreover, inhibition of P-TEFb has been shown to downregulate the expression of EMT transcription factors (Slug, FOXC2, ZEB2, and Twist1), thus delaying tumor progression (Ji et al., 2014) . Our new data show that CDK9-targeting reactivates tumor-suppressor genes and induces a cellular immune response that may sensitize to checkpoint inhibitors. Thus, CDK9, which is overexpressed in many cancers (based on cBioPortal) (Cerami et al., 2012; Gao et al., 2013) , has multiple properties that make it an excellent target for drug development in cancer.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines and cell culture YB5 cell line was derived from SW48 (female) colon cancer cell line in our lab (Si et al., 2010) . SW48/YB5 cells were maintained in L-15 (Corning) supplemented with 10% FBS (Atlanta Biologicals) and 1% penicillin/streptomycin (Corning) at 1% CO 2 in 37 C. MCF7-GFP cell line was derived from MCF7 (female) breast cancer cell line in our lab. HCT116-GFP (male) colon cancer cell line (Cui et al., 2014) was provided by Dr. Stephen Baylin (Johns Hopkins University). Prostate cancer cell lines DU145 (male) and LnCaP (male), a normal fibroblast cell line IMR90 (female), HEK293T (female) and leukemia cell lines KG-1 (male) and HL-60 (female) were obtained from ATCC. HEK293T, HCT116/HCT116-GFP, MCF7/MCF7-GFP, IMR90, LnCaP and DU145 cells were cultured in DMEM (Corning), McCoy's 5A (Corning), DMEM (Corning), MEM (Corning), RPMI-1640 (Corning) and MEM (Corning) respectively, with 10% FBS and 1% penicillin/streptomycin at 37 C in 5% CO 2 . KG-1 and HL-60 were cultured in IMDM supplemented with 20% FBS at 37 C in 5% CO 2 . Mouse ovarian cancer ID8 (female) cells were provided by Dr. Cynthia Zahnow (Johns Hopkins University) and grown in RPMI 1640, 10% FBS and gentamicin sulfate (5mg/mL) (Corning) at 5% CO 2 in 37 C.
NSG mice treated with MC180295
SW48-luc cell line was generated by transfecting pFUGW-FerH-ffluc2-eGFP into SW48 cells. GFP positive cells were sorted out one week after transfection and expanded for the in vivo experiments. Both female and male NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NSG) mice were used for the experiment. Age and gender matched mice were randomly assigned to each group. Experimental protocols were approved by the Temple University's Committee on Use and Care of Animals. 8-10-week-old NSG mice were inoculated (i.p.) with 1310 5 SW48-luc cells. One week later, at which time substantial tumor burden was evident by bioluminescence imaging, mice were randomized and 5-20mg/kg MC180295 or drug solvent was administered (i.p.) every other day. 200uL of diluted PierceÔ D-Luciferin, Monosodium Salt (Thermo Fisher Scientific) (working concentration: 15mg/mL) was administered (i.p.) into each mouse and was imaged using IVIS imaging system 5 minutes after the administration. Three vehicle treated mice and five drug treated mice were used in this study. Natural death or accumulation of ascites fluid was used as the endpoint for this model.
For the s.c. SW48 model, 2310 6 cells were injected into the flank of randomly assigned gender-matched 8-10-week-old NSG mice. 20mg/kg MC180295 was injected (i.p.) every other day when the tumors were palpable 9 days after engraftment. Seven mice were used in each group for this experiment and they were sacrificed before tumors volumes exceeded 400 mm 2 . MC180295 was dissolved in NMP (Fisher Scientific), Captisol (20% w/v) (CyDex), PEG-400 (Millipore Sigma) and normal saline (PBS) (Corning) in a ratio of 1:4:4:11. NMP first, followed by Captisol and PEG-400. PBS was added last.
Humanized PBMC NSG mice treated with MC180295 Human PBMCs were isolated from blood samples collected from healthy adult donors (two donors total) under an institutional review board (IRB) approved protocol (Temple University). 20 million human PBMCs were injected (i.p.) on day 0 into 8-10-week-old female randomly assigned NSG mice. 20mg/kg MC180295 were injected (i.p.) every other day for 12 days and whole blood was collected on day 14 followed by flow cytometry analysis.
MC180295 was dissolved in NMP (Fisher Scientific), Captisol (20% w/v) (CyDex), PEG-400 (Millipore Sigma) and normal saline (PBS) (Corning) in a ratio of 1:4:4:11. NMP first, followed by Captisol and PEG-400. PBS was added last.
Pharmacodynamics study in NSG mice treated with MC180295
Six gender-matched 8-10-week-old NSG mice were randomly assigned to two groups (Vehicle vs. Drug treatment). 2310 6 cells were injected into the flank of NSG mice, 20mg/kg MC180295 was injected (i.p.) every other day when the tumors were palpable 9 days after engraftment for two weeks. Tumors were then collected, homogenized (FastPrep-24 homogenizer) and total mRNA was extracted followed by qPCR.
Mouse experiments with in vivo treatment of SNS-032 2.5x10 5 ID8-VEGF-Defensin cells were injected i.p. into 7-8-week-old randomly assigned female C57BL/6NHsd (C57Bl/6) mice. All animal experiments were approved by the Johns Hopkins Animal Care and Use Committee. All animal care and protocols followed were in accordance with guidelines of the institutional Animal Care and Use Committee (IACUC). Three days after injection, 1 mg/kg SNS-032 (Selleckchem), 10 mg/kg SNS-032, or 5% DMSO in PBS (vehicle control) was administered i.p. every 3 days for the duration of the experiment.a-PD-1 (200ug/mouse) or IgG control (Leinco Technologies) were given on days 17, 20, 24, and 27 after injection.a-PD-1 (1mg/mL in saline) was kindly provided by Dr. Michael Lim of the SKCCC, Johns Hopkins University. Mouse IgG isotype control was diluted in PBS.
METHOD DETAILS
NDL-3040 library screening and drug treatments NDL-3040 compound library consists of 3040 chemically diverse compounds that are semi-natural, derived from natural compounds, or synthetic compounds that are natural-compound-like.The small molecules were arrayed in 96-well plates as 10mM stocks in 100% DMSO and were purchased from TimTec Inc. An aminothiazole analog library (93 small molecules) was also purchased from the same vendor and was in a 96-well plate format as 10mM stocks in 100% DMSO. The 3040 compounds were screened at 25mM for 24hr. All plates were kept at -80 C before use.YB5 cells growing in log phase (70-80% confluency) in 96-well plates were used. Each experimental 96-well plate contained 80 different compounds. A negative control (DMSO) and a positive control (5mM TSA) were placed at the edges as shown in Figure S1A . Compounds were dispensed using an INTEGRA VIAFLO96 96-well pipette. After a 24hr drug treatment, cells were trypsinized for 10 mins and re-suspended in L-15 medium containing propidium iodide (PI) to stain for dead cells. A total of 10000 cells per well were analyzed using Millipore Guava flow cytometer (EMD, Millipore). GFP positive percentage was calculated by excluding all the PI positive cells. After finishing the screening, the average Z-factor (Z-factor =1 À ð3ðs p + s n Þ= m pÀ m n Þ ) was calculated to test the robustness of the assay (the means (m) and standard deviations (s) of both the positive control (TSA) and negative controls (DMSO) (m p , s p and m n s n )). For a single-dose, four-day treatment schedule, different drugs were added 24 hours after cell seeding, drug-free medium was replenished three days later, and downstream experiments were performed on the following day. For daily treatment schedules, drug-free media were changed every day before supplementing new drugs. All drugs were originally in 100% DMSO stocks. The final concentration of DMSO in drugtreated cultures was 0.5%. Eighteen compounds identified as positive hits by the screening were purchased in powder form from TimTec Inc for validation. Several multi-CDK inhibitors (alsterpaullone (Sigma-Aldrich), GW8510 (Sigma-Aldrich), roscovitine (Millipore Sigma), RGB286147 (Millipore Sigma), dinaciclib (Selleckchem), SNS-032 (Selleckchem), iCDK9 (Chemscene, LLC) and flavopiridol (Santa Cruz Biotechnology) were also purchased and used in this project. Other chemicals used include PFI-3 (Selleckchem), CHIR99021 (Cayman), trichostatin A (TSA) (Sigma-Aldrich), SAHA (Sigma-Aldrich), depsipeptide (Sigma-Aldrich), valproic acid (Sigma-Aldrich), decitabine (DAC, Sigma-Aldrich) and tretinoin (ATRA, Selleckchem). All the compounds above were dissolved in 100% DMSO at 10mM stock concentration except for ATRA (dissolved in ethanol) and DAC (dissolved in water).
DNA extraction and DNA methylation analysis DNA extraction, bisulfite conversion, and pyrosequencing were described and all primers were listed previously (Si et al., 2010) . In brief, cell pellets were lysed in 600 microliters of the cell lysis solution (2% sodium dodecyl sulphate, 25 mM EDTA, pH 8.0). Two microliters of proteinase K (20 mg/ml) were added and the lysate were incubated at 55 C for 1 hour. One microliter of RNase A (100 mg/ml) was added afterwards and the lysate was incubated at 37 C for 15 minutes. Proteins were precipitated by adding 200 microliters of 10 M ammonium acetate. The tubes were cooled on ice and centrifuged at 12,000 rpm for 15 minutes. Supernatant containing DNA was poured in a tube containing 600 microliters of isopropanol. DNA was precipitated by inversion of the tube and brief vortexing. Precipitated DNA was pelleted by centrifugation, washed with 70% ethanol, and dissolved in 100 microliters of TE (TRIS 10 mM, EDTA 1 mM, pH 8.0). After DNA extraction, one microgram of genomic DNA was treated with bisulfite using the Epitect kit (QIAGEN). Bisulfite-treated DNA (40-80 ng) was amplified with gene-specific primers in a 2-step polymerase chain reaction (PCR). The second step of PCR was used to label single DNA strand with biotin using a universal primer tag. We measured levels of DNA methylation as the percentage of bisulfite-resistant cytosines at CpG sites by pyrosequencing with the PSQ HS 96 Pyrosequencing System (QIAGEN) and Pyro Gold CDT Reagents (QIAGEN). We found high concordance in methylation between adjacent CpG sites and therefore used mean values from all pyrosequenced CpG sites as a measure of methylation of a given gene.
siRNA Knockdown ON-TARGETplus Non-targeting siRNA (siN) (D-001810-10) , SMARTpool siSMARCA4 (L-010431-00-0005) and CDK9 (L-003243-00-0010) were ordered from GE Dharmacon and diluted in water. Transfection was performed using Lipofectamineâ RNAiMAX Reagent (ThermoFisher Scientific) according to the manufacturer's instructions at a 20nM final working concentration.
Plasmids transfection and viral transduction
Cells were transfected with Cdc2-DN-HA, CDK2-DN-HA, Rc-dnCDK9, pCMV5 FLAG-BRG1, GFP-CDK9 and FLAG-CDK9 plasmids for 72hr to overexpress dnCDK1, dnCDK2, dnCK9, BRG1, and CDK9 using Lipofectamine 2000 (ThermoFisher Scientific) according to the manufacturer's instructions. V5-tagged wild-type BRG1, 5STOA-BRG1 and NO5S-BRG1 constructs were transfected using Lipofectamine 2000 (ThermoFisher Scientific) according to the manufacturer's instructions for 48hr prior to drug treatment for another 48hr.YB5 and HCT116-GFP cells were infected with Ad-T-dnCDK9 plus Adeno-XÔ Tet-OffÔ adenoviruses (dnCDK9) in the presence or absence of doxycycline (tet) as previously described (Garriga et al., 2010) for 72hr before processing for analysis. Wild type Ad-CyclinT1 and Ad-CDK9 were also transduced for 72hr to overexpress CyclinT1 and CDK9 (Garriga et al., 2003) . Cdc2-DN-HA (#1889), CDK2-DN-HA (#1885), and pCMV5 BRGI-Flag (#19143) plasmids were purchased from Addgene. GFP-CDK9 and FLAG-CDK9 plasmid were a generous gift from Bassel E. Sawaya, Temple University. V5-BRG1 construct was a generous gift from Cigall Kadoch, Dana-Farber Cancer Institute.
Biochemistry assays HDAC inhibitory activity assays were performed using FLUOR DE LYSâ HDAC fluorometric activity assay kit (ENZO) following the manufacturer's instructions. GloMaxâ-Multi Detection System (Promega) was used to read the fluorescence signals. Histone methyltransferase and demethylase enzymatic assays were performed by BPS Bioscience at 10mM in duplicates (Table S3) . Briefly speaking, all assays were performed in a 50ml mixture containing proper methyltransferase assay buffer, S-adenoslymethionine (BPS number 52120), enzyme (HMTs or HDMs), and the test compound (either HH0 or HH1 at 10mM) at room temperature in a substrate pre-coated plate. After enzymatic reactions for 60-960 minutes, reaction mixtures were discarded, wells were washed three times with Tris Buffered-saline Tween (TBST) buffer, and slowly shaken with Blocking Buffer (BPS catalog number 52100) for 10 minutes. Then, wells were emptied and 100 ml of diluted primary antibody was added. The plate was then slowly shaken for 60 minutes at room temperature, washed three times using TBST, and shaken with Blocking Buffer for 10 minutes at room temperature. After discarding the Blocking Buffer, 100 ml of diluted secondary antibody was added and the plate was shaken for 30 minutes at room temperature. Then, the plate was washed three times using TBST, and shaken with Blocking Buffer for 10 minutes at room temperature. Blocking Buffer was discarded and 100 ml of freshly prepared mixture of the HRP chemiluminescent substrates was added to each empty well. Immediately, sample luminescence was measured using a BioTek SynergyTM 2 microplate reader. The percent activity in the presence of each compound was calculated according to the following equation: % activity = (C-C0)/(Ce-C0), where C= the luminescence or A-screen intensity in the presence of the compound. The intensity (Ce) in each data set was defined as 100% activity in the absence of the compound. In the absence of enzyme, the intensity (C0) in each data set was defined as 0% activity. Kinase enzymatic assays were performed by Nanosyn using microfluidic technology. Briefly speaking, the in vitro kinase assay was performed using the microfluidic mobility shift platform of PerkinElmer. The target kinase was incubated with fluorescently labeled substrate and MC180295 in a standardized reaction mixture in a 384 well plate. Upon termination of the enzymatic reaction, samples were loaded onto microfluidic chips. Samples then migrated through channels and product and substrates were separated based on the difference in their charge. Enzyme activity was determined by comparison of the fluorescence in the product and substrate peaks. 250 kinome screening was done in duplicates using MC180295 at 1mM (Table S4 ). IC50 curves against 10 CDKs were created for MC180295. The human kinome tree was annotated using the online Kinome Render software (Chartier et al., 2013) . Isotope kinase assay was performed as previously described (Garriga et al., 1998) using recombinant active full-length CDK9/CyclinT1 (Thermo Fisher Scientific) and BRG1 (Abcam) in the presence or absence of CDK9 inhibitors. Briefly speaking, 1.2mg of purified CDK9/Cyclin T1 (Thermo Fisher Scientific) was pre-incubated in the presence or absence of either 1mM of MC180295 or 1mM of FVP for 15min. Then, 0.8 mg of purified BRG1 (Abcam) was added and incubated at 30 oC for 1hr in KAS buffer (with 5mCi/ml of 32 g-ATP). The reaction was stopped by heating the samples at 65 oC for 5min.
Synthesis of MC180295
Step 1 (4-amino-2-(methylthio)thiazol-5-yl)(2-nitrophenyl)methanone A solution of (4-amino-2-(methylthio)thiazol-5-yl)(2-nitrophenyl)methanone (0.1693 mmol; 50 mg) and exo-2-aminonorbornane (3.386 mmol; 401 ml) in ethanol (2 ml) was stirred at 100 o C in a glass pressure vessel overnight. This solution was cooled to room temperature and concentrated down. The crude product was purified by flash column chromatography on silica gel using a gradient solvent system of 0 to 100% of ethyl acetate in hexanes to afford the titled compound as an orange glassy solid. 
Flow cytometry
For drug screening and dose response validations, GFP positive cells were detected by Millipore Guava flow cytometer (EMD, Millipore) . Cell cycle analysis was performed using BD FACSCaliburÔ by propidium iodide staining four days after drug treatment. Sub-G1 population percentage was also included to measure apoptotic cell proportion. Data were analyzed using FlowJo software version 10.2. For the cell differentiation analysis, cells were washed and stained with propidium iodide (PI), CD11b (BD Biosciences) and the isotype control IgG (BD Biosciences). Flow cytometry analysis was performed on a Millipore Guava flow cytometer (EMD, Millipore) . For the ID8 in vivo experiments, ascites was drained from 5-10 mice per group and incubated in ACK buffer (Thermo Fisher) to lyse red blood cells for 10 minutes, then washed. Ascites from each mouse was individually lysed and prepared for flow cytometry. Mononuclear cells collected were cultured for 4 hours in RPMI with 5% Fetal Bovine Serum and in the presence of Cell Stimulation Cocktail (plus protein transport inhibitors; eBioscience). Cells were then washed and stained for cell surface markers including Live/ Dead (eBioscience), CD45 (BD Biosciences), CD3 (BD Biosciences), MHC II (Pacific BlueÔ anti-mouse I-A/I-E Antibody, Isotype Control: Pacific BlueÔ Rat IgG2b, k Isotype Ctrl Antibody), CD80 (BD Biosciences), CD86 (BD Biosciences) and CD11c (BD Biosciences). Flow cytometry acquisition was performed on an LSRII cytometer (BD Biosciences) and data were analyzed using FlowJo software version 10.2. For the PBMC in vivo experiments, whole blood was collected from healthy donors and processed using FicollPaque PLUS (GE Healthcare) following the manufacture's protocol. Fourteen days after injection, blood was collected from tail vein, lysed using ACK lysing buffer and prepared for flow cytometry. Cells were stained for cell surface markers including CD45 (Biolegend), CD4 (Biolegend) and CD8 (Biolegend). Flow cytometry acquisition was performed on an LSRII cytometer (BD Biosciences) and data were analyzed using FlowJo software version 9.9.4.
Nuclear Extract Preparation
Cells were homogenized in Buffer A (25 mM HEPES (pH 7.6), 25 mM KCl, 0.05 mM EDTA, 10% glycerol, 5mM MgCl 2 , 0.1% NP-40, supplemented with fresh 1mM DTT, protease inhibitors [Roche] , and 1mM PMSF) on ice. Nuclei were sedimented by centrifugation (1,200 rpm), resuspended in Buffer C (10 mM HEPES (pH 7.6), 3 mM MgCl 2 , 100 mM KCl, 0.1 mM EDTA, 10% glycerol, 1 mM DTT and protease inhibitors), and lysed by the addition of ammonium sulfate to a final concentration of 300 mg/mL. Soluble nuclear proteins were separated by ultracentrifugation (100,000 x g) and precipitated with 0.3 mg/ml ammonium sulfate for 20 min on ice. Protein precipitate was isolated by ultracentrifugation (100,000 x g) and resuspended in IP buffer (300 mM NaCl, 25 mM HEPES [pH 8.0], 0.1% Tween-20, 10% Glycerol, 1 mM DTT, 1 mM PMSF with protease inhibitors).
Co-immunoprecipitation
Endogenous Co-IP experiments were performed in HEK293T and SW48 cells using BRG1 (Santa Cruz, #sc-17796), CDK9 (Santa Cruz, #sc-484), BAF155 (Cell Signaling, #11956), CyclinT1 (Santa Cruz, #sc-10750), BAF60a (Santa Cruz, #sc-135843) antibodies.Exogenous co-IP studies were performed in HEK293T and SW48 cells using BRG1 (Santa Cruz, #sc-17796), CDK9 (Santa Cruz, #sc-484), FLAG-M2 (Sigma, #F-1804) and GFP (NOVUS, #NB-100) antibodies. HEK293T cells were transiently transfected with either an empty vector (EV) or a FLAG-tagged CDK9. SW48 cells were transiently transfected with an empty vector (EV), a FLAG-tagged BRG1 or a GFP-tagged CDK9.
Nuclear extracts were resuspended in IP buffer and placed in protein low-bind tubes (Eppendorf). We quantified protein by standard BCA protocol (Pierce-23225, Thermo Scientific). Cell extracts were incubated with the corresponding IP antibodies. Separate lysate tube was prepared from samples for incubation with species-matched normal mouse IgG. Samples were incubated overnight with gentle rotation at 4 C. Protein G Dynabeads (Life Technologies) were incubated with the antigen-antibody complex for 2.5 hours the following day. Beads were washed four times with lysis buffer with gentle agitation for 5 minutes per wash. 2x Laemmli sample buffer (Bio-Rad) was used for elution of complex from beads followed by Western blotting along with the nuclear extract as inputs.
Generation of 5STOA and NO5S BRG1 constructs
The recombinant wild type BRG1 construct was generated using a plasmid PLEX 307 containing the open reading frame of the human SMARCA4/BRG1 gene (V5-BRG1). A mutant lacking the amino acids 1570-1631 (Called NO5S) and a mutant with substitutions of serine by alanine in positions 1570 , 1575 , 1586 , 1627 , 1631 were used in the paper. The amino acid positions are based on the Uniprot (www.uniprot.org) canonical notation sequence # P51532-1.
For generating the mutants, the PLEX307 plasmid containing the SMARCA4 gene (V5-BRG1) was co-digested with FspAI and Eco32I (Thermofisher) and the mutations were inserted by ligating synthetic constructs (gblocks by IDT DNA Technologies) containing the desire mutations using the Gibson assembly method (Gibson et al., 2009) For the Gibson assembly of each mutant, 50 ng of digested vector were ligated with 37.5 ng of the common gblock and 37.5ng of the gblock of each mutant by using the Nebuilder HIFI DNA assembly master mix (New England Biolabs) following the manufacturer's instructions. After 1 hour of incubation at 50 deg celcius, $3 ml of the reaction mixture was used to transform STBL3 competent cells (Thermo Fisher) and selected in carbenicillin-agar plates. Overexpression of these plasmids was verified by western blot using an anti-V5 antibody (Thermo Fisher).
Cell microscopy and High Content Imaging Analysis YB5 cells were seeded in 96 well plates for high content imaging (Cell Carrier Ultra by Perkin Elmer) and each well was individually transfected with 100 ng of the plasmids using Lipofectamine 2000 following the manufacturer's instructions. 48 hours after transfection, YB5 cells were treated with either DMSO, 500nM MC180295 or 500nM iCDK9 for an additional 48 hours before being processed for cell microscopy. For the microscopy analysis, Hoechst 33342 was added into every well at a final concentration of 1 mg/ml, followed by incubation at 37 degrees Celsius for 20 minutes. Microscopic image acquisition was then performed using a confocal Operetta CLS-Live High Content Imaging System (Perkin Elmer -model # HH16000000) equipped with temperature and CO 2 environment control for live cells. The images were acquired with a 20X water immersion objective by using the following combination filter settings for fluorescence imaging: Hoechst Nuclear staining was detected with a 406/450 nanometer wavelength excitation/emission filter setting. GFP expressing cells were detected with a 488/513 nanometer wavelength excitation/emission filter setting. Image capture and analysis were performed with Harmony 4.6 software (Perkin Elmer). For this analysis, the instrument was setup to capture sixteen high resolution images per well on the same location in every well across all the experimental plates. Cell numbers and GFP quantifications across all experimental conditions were detected using Harmony 4.6 image analysis module. qPCR Total RNA was extracted using TRIzol reagent (Invitrogen) following the manufacturer's protocol and RNA concentrations were measured using Nanodrop. cDNAs were synthesized using High Capacity cDNA Reverse Transcription Kit (ThermoFisher) and qPCR was performed using either ready-made TaqManâ assays or SYBR-green using custom-designed primers. All the data were analyzed using Applied Biosystems software (StepOne TM Software V2.3). For all experiments, relative expression levels of the target genes were determined by calculating the 2 -DCt values. All experiments were performed at least in triplicates. Either GAPDH or 18S rRNA was used as an internal normalization control for protein coding genes. RPLPO was used as an internal normalization control for ERVs. All SYBR-green primers were described previously and are listed in Table S1 along with TaqManâ probes used.
Anti-proliferation assay Cells were seeded in 96-well plates at 40% confluency. Fresh medium was changed the next day and drugs were added directly. After mixing thoroughly, plates were cultured in a 37 C incubator for two more days. Drug-free fresh medium was changed the fourth day. The cells were collected on day 5 by trypsin, suspended in medium, mixed with trypan blue (Thermo Fisher Scientific) (1:1 ratio), and counted using LUNA II automated cell counter. Each sample was counted at least three times and the average numbers were used for the analysis. Each treatment condition was performed in triplicates.
Soft Agar Colony Formation Assay
Cells for colony-formation assays were pretreated with different concentrations of HH1 and MC180295 and drugs were kept in the medium for two more days and drug-free medium was changed the day before seeding (four days total). 1000 cells were then seeded in 35mm310mm tissue culture dishes and cultured in a 37 C incubator for two weeks before staining using 0.005% crystal violet (dissolved in autoclaved water with 10% EtOH). Difco TM Agar Noble (BD Biosciences) was used to make soft agar. 2x medium supplemented with 20% FBS and 2% penicillin/streptomycin was used to culture colonies. Bottom layer was made of 0.6% agar and top layer was made of 0.3% agar. Feeder layer with 0.3% agar was added every week. All visible colonies were counted manually.
Histone extraction
Histones were extracted and prepared from isolated nuclei as described previously (Sidoli et al., 2016) . Briefly, nuclei were incubated with 0.2 M H 2 SO 4 for 2 hours and precipitated with 33% trichloroacetic acid (TCA) overnight to extract histones from the chromatin.
Purified histones were dissolved in 30 mL of 50 mM NH 4 HCO 3 , pH 8.0, and a mixture of propionic anhydride with acetonitrile (ratio of 1:3 (v/v)) was added to the histone sample in the ratio of 1:4 (v/v) for 20 minutes at room temperature. This reaction was performed twice. Histones were then digested with trypsin (enzyme:sample ratio 1:20, 6 hours, room temperature) in 50 mM NH 4 HCO 3 . After digestion, derivatization was repeated to propionylate peptide N-termini. Samples were desalted prior LC-MS analysis using C18 Stage-tips.
Mass Spectrometry Analysis
Samples were then separated using a 75 mm ID x 17 cm Reprosil-Pur C18-AQ (3 mm; Dr. Maisch GmbH, Germany) nano-column mounted on an EASY-nLC nanoHPLC (Thermo Scientific, San Jose, Ca, USA). The HPLC gradient was as follows: 2% to 28% solvent B (A = 0.1% formic acid; B = 95% MeCN, 0.1% formic acid) over 45 minutes, from 28% to 80% solvent B in 5 minutes, 80% B for 10 minutes at a flow-rate of 300 nL/min. nLC was coupled online to an LTQ-Orbitrap Elite mass spectrometer (Thermo Scientific) and data were acquired using targeted scans and data-dependent acquisition (DDA). MS acquisition was divided into three segments, each beginning with a full MS scan: (i) MS/MS of the top seven most abundant ions (14 min), (ii) targeted CID fragmentation of common isobaric species (H3 peptide aa 9-17 with 1 acetyl, H3 peptide aa 18-26 with 1 acetyl and histone H4 peptide aa 4-17 with 1/2/3 acetyl groups) followed by CID fragmentation of the top five most abundant ions (27 min), (iii) CID fragmentation of the top ten most abundant ions (19 min). MS/MS was acquired using collision induced dissociation (CID) with normalized collision energy of 35 and collected in centroid mode. Data were searched using EpiProfile (Yuan et al., 2015) . The peptide relative ratio was calculated using the total area under the extracted ion chromatograms of all peptides with the same amino acid sequence (including all of its modified forms) as 100%. For isobaric peptides, the relative ratio of two isobaric forms was estimated by averaging the ratio for each fragment ion with different mass between the two species. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE (Vizcaíno et al., 2016) partner repository with the dataset identifier PXD007925 and 10.6019/PXD007925.
In Vitro Phosphoproteomics
An in vitro kinase assay was performed using purified CDK9/Cyclin T1 (4.8mg) (Thermo Fisher Scientific)and BRG1 (3.2mg) (Abcam), in the presence or absence of 1mM of MC180295 using KAS buffer (with ''cold'' ATP) and incubate at 30 oC for 1hr in quadruplicate. Protein reaction was stopped by heating at 65 oC for 5 minutes and samples were desalted using 3kDa cutoff filter (nanosep 3K Omega PALLâ). Samples were processed for mass spectrometer analysis using in-StageTip method for digestion and peptide purification before performing LC-MS/MS proteomics analysis. The label-free proteomics analysis was performed using the nanoelectrospray ionization (ESI) tandem MS with a LTQ Orbitrap Elite mass spectrometer (Thermo Scientific). The complete system was fully controlled by Xcalibur software (Version 3.0.63). Mass spectra processing was performed using Proteome Discoverer 2.2.0.388. The generated de-isotoped peak list was submitted to an in-house Mascot Server 2.2.07 for searching against the Homo sapiens SwissProt database (TaxID=9606, released 2017-05-10. 42,153 sequences). Mascot search parameters were set as follows: species, Homo sapiens; enzyme: trypsin; maximal two missed cleavage; dynamic modifications: phospho (S, T) and phospho (Y); mass tolerance: 20 ppm for precursor peptide ions and 0.4 dalton tolerance for MS/MS fragment ions. Phosphopeptides matches were filtered using an ion score cutoff of 20. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE (Vizcaíno et al., 2016) partner repository with the dataset identifier PXD009573.
ChIP-qPCR
Chromatin immunoprecipitation (ChIP) was performed as described previously (Raynal et al., 2012) using antibodies for anti-histone H3K4me2 (Abam) and anti-histone H3K9 dimethylation (Abcam). In brief, YB5 cells were fixed with 1% formaldehyde, sonicated in SDS lysis buffer (1% SDS, 10uM EDTA, 50uM Tris pH 8.1) and immunoprecipitated using different antibodies. DNA was extracted using a QIAquick PCR Purification Kit (QIAGEN). Signal was quantified by qPCR and normalized using % of input. All ChIP primers are listed in Table S2 .
QUANTIFICATION AND STATISTICAL ANALYSIS
RNA-seq RNA from experiments in biological triplicates was isolated using RNeasy Mini Plus Kit (QIAGEN) following the manufacturer's instructions. Strand-specific RNA libraries were generated from 1 mg of RNA using TruSeq stranded total RNA with Ribo-Zero Gold (Illumina). Sequencing was performed using single end reads (50 bp, average 50 million reads per sample) on the HiSeq2500 platform (Illumina) at Fox Chase Cancer Center Genomic Facility. Sequenced reads were aligned to the hg19 genome assembly using TopHat2 (Kim et al., 2013) . The expression level and fold change of each treatment group was evaluated using EdgeR (Robinson et al., 2010) . Genes that had 0 reads across all samples were excluded. In order to get rid of batch effects, samples were normalized using RUVr method from the RUVseq package (Risso et al., 2014) . For the repetitive element analysis, RNAseq reads were mapped against known repetitive element sequences and data were normalized with the total number of mappable reads. Significantly regulated genes were defined as log2FC >1 or < -1, and FDR < 0.5. All the RNA-seq data were normalized to time-matched DMSO samples for each time point, while TET-off dnCDK9 was normalized to TET-on dnCDK9.
RRBS
Triplicate samples of YB5 cells treated with 10 mM HH1 and DMSO controls were analyzed for DNA methylation changes by reduced representation bisulfite sequencing (RRBS) (Gu et al., 2011) . We followed the NEB protocol for methylated adaptors. Briefly, 1 microgram of genomic DNA was spiked 100 picograms of lambda phage DNA as the unmethylated standard and digested with MspI. Ends of restriction fragments were filled in, 3'-dA tailed and methylated adaptors (NEB E7535) were ligated to the ends of restriction fragments. Bisulfite treatment using the Epitect kit (Qiagen) followed. Bisulfite-converted libraries were amplified using EpiMark Taq DNA polymerase (NEB) and primers with barcode indices. The libraries were pooled and sequenced at Fox Chase Cancer Center Genomics Facility on Illumina HiSeq2500 instrument using single end reads of 50 bases. We used Bismark v0.18.1 (Krueger and Andrews, 2011) to align the sequences to hg19 human genome assembly. We used methylKit v1.3.3 (Akalin et al., 2012) to analyze differential methylation. Logistic regression was used to calculate P-values. P-values were adjusted to Q-values using SLIM method (Wang et al., 2011) .
Digital restriction enzyme analysis of methylation (DREAM) DREAM is a method established in our lab for DNA methylation analysis at tens of thousands of CpG sites across the genome (Jelinek et al., 2012) . Sequential digests of genomic DNA with restriction endonucleases SmaI and XmaI creates specific signatures at unmethylated and methylated CpG sites. The signatures are resolved by high throughput sequencing.Briefly, two samples of 2 mg of genomic DNA from ID8 ovarian cancer cell line were digested with 20 units of SmaI (8 h at 25 C, NEB) and 20 units of XmaI ($16 h at 37 C, NEB), resulting in distinct DNA methylation signatures at CCCGGG sites. 3' ends of the DNA fragments were repaired using Klenow fragment (3'/5' exo-) DNA polymerase and dCTP, dGTP, and dATP nucleotides. Illumina sequencing adapters were ligated to the DNA fragments and the libraries were sequenced by paired-end 40 nt sequencing on Illumina HiSeq2500.The sequencing reads were mapped to the mm9 genome and methylation values were calculated as the ratio of the number of the reads with the methylated XmaI signature over the total number of tags mapped to a given SmaI/XmaI site. The coverage threshold was set to greater than 10 reads per sample.
By concatentating the protein structure from human CDK9 bound to ATP with the MC180295 pose from aligning to these 389 ligand templates, this approach provided a set of complete, but unrefined, comparative modeling templates. We carried out a full-atom gradient-based energy minimization for each complex using the Rosetta macromolecular modeling suite (Leaver-Fay et al., 2011) , then sorted the resulting models on the basis of protein-ligand interaction energy. Four of the top-scoring ten models adopted a nearly identical pose, whereas the other six had a broad variety of other poses. Based on consistency with the available structure-activity data, we confirmed this dominant cluster as the most likely pose (as described in the Main Text).
TCGA analysis RNA-seq data for melanoma and colon cancer patients were downloaded from the TCGA data portal. Unsupervised hierarchical clustering was performed using ArrayTrack. Cox regression analyses and Kaplan-Meier curves were generated for CIM-high and CIM-low patients.
RNA-seq data from anti-CTLA4 treated melanoma patients Patients were described previously (Chiappinelli et al., 2015) . RNA-seq data were downloaded from dbGaP (phs001038). Unsupervised hierarchical clustering was performed using ArrayTrack.
All statistical analysis were calculated using the GraphPad Prism software. Student's t-test was used to calculate significance between two groups and One-way ANOVA test was used to calculate differences for more than two groups.
For Figure 1 , in all panels, *p<0.05, **p < 0.01, ***p < 0.001. One-way ANOVA, Dunnett's multiple comparison test was used in Figures 1A-1C while Student's t-test was used in Figures 1D and 1E . Bar graphs represent mean+SD of at least biological triplicates.
For Figure 5 , in all panels, *p<0.05, **p < 0.01, ***p < 0.001. Student's t-test was used in Figure 5A while One-way ANOVA, Dunnett's multiple comparison test was used in Figures 5B-5D . Bar graphs represent mean+SD of at least biological triplicates.
One-way ANOVA, Dunnett's multiple comparison test was also used in Figures 2A and 6B . Student's t-test was used in Figure 4H and Mann Whitney test was used in Figure 6D . 
